甲钴胺联合依帕司他治疗糖尿病周围神经病变:降低炎症因子,改善肌电指标。

IF 1.6 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
American journal of translational research Pub Date : 2025-04-15 eCollection Date: 2025-01-01 DOI:10.62347/XUBX8834
Lu Song, Jing Ye, Qun Cheng
{"title":"甲钴胺联合依帕司他治疗糖尿病周围神经病变:降低炎症因子,改善肌电指标。","authors":"Lu Song, Jing Ye, Qun Cheng","doi":"10.62347/XUBX8834","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical efficacy of mecobalamin combined with epalrestat in treating diabetic peripheral neuropathy (DPN) and its effects on inflammatory factors and electromyogram (EMG) indices.</p><p><strong>Methods: </strong>Data from 100 DPN patients treated at Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital between June 2021 and December 2022 were retrospectively analyzed. Among them, the control group was 45 patients treated with mecobalamin alone. 55 patients treated with epalrestat, in addition to mecobalamin, were the observation group. Outcomes compared between the two groups included the changes in inflammatory factors, EMG indices, oxidative stress markers, blood glucose levels before and after treatment, clinical efficacy, and the incidence of adverse reactions.</p><p><strong>Results: </strong>The observation group showed a significantly higher overall response rate than the control group (P<0.05). After treatment, the observation group exhibited lower levels of C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), and matrix metalloproteinase-9 (MMP-9) than control group (all P<0.05). The observation group also demonstrated higher motor nerve conduction velocity (MCV) and sensory nerve conduction velocity (SCV) of the median nerve and nervus peronaeus communis compared to the control group (all P<0.05). Additionally, the observation group showed lower levels of propylene glycol and higher levels of superoxide dismutase compared to the control group (both P<0.05). Fasting blood glucose and 2-hour postprandial blood glucose levels in the observation group were significantly lower than those in the control group (P<0.05). Both groups exhibited a decrease in Michigan Diabetic Neuropathy Scores post-treatment compared to pre-treatment, with the observation group scoring lower than the control group (P<0.05). No difference was found between the 2 groups in the incidence of adverse reactions (P>0.05).</p><p><strong>Conclusion: </strong>Mecobalamin combined with epalrestat substantially alleviates DPN, improves electromyogram indices, and reduces inflammatory factors and oxidative stress response, without increasing adverse reactions.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 4","pages":"2898-2906"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082505/pdf/","citationCount":"0","resultStr":"{\"title\":\"Therapeutic effects of mecobalamin combined with epalrestat on diabetic peripheral neuropathy: reduction of inflammatory factors and improvement in electromyogram indices.\",\"authors\":\"Lu Song, Jing Ye, Qun Cheng\",\"doi\":\"10.62347/XUBX8834\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the clinical efficacy of mecobalamin combined with epalrestat in treating diabetic peripheral neuropathy (DPN) and its effects on inflammatory factors and electromyogram (EMG) indices.</p><p><strong>Methods: </strong>Data from 100 DPN patients treated at Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital between June 2021 and December 2022 were retrospectively analyzed. Among them, the control group was 45 patients treated with mecobalamin alone. 55 patients treated with epalrestat, in addition to mecobalamin, were the observation group. Outcomes compared between the two groups included the changes in inflammatory factors, EMG indices, oxidative stress markers, blood glucose levels before and after treatment, clinical efficacy, and the incidence of adverse reactions.</p><p><strong>Results: </strong>The observation group showed a significantly higher overall response rate than the control group (P<0.05). After treatment, the observation group exhibited lower levels of C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), and matrix metalloproteinase-9 (MMP-9) than control group (all P<0.05). The observation group also demonstrated higher motor nerve conduction velocity (MCV) and sensory nerve conduction velocity (SCV) of the median nerve and nervus peronaeus communis compared to the control group (all P<0.05). Additionally, the observation group showed lower levels of propylene glycol and higher levels of superoxide dismutase compared to the control group (both P<0.05). Fasting blood glucose and 2-hour postprandial blood glucose levels in the observation group were significantly lower than those in the control group (P<0.05). Both groups exhibited a decrease in Michigan Diabetic Neuropathy Scores post-treatment compared to pre-treatment, with the observation group scoring lower than the control group (P<0.05). No difference was found between the 2 groups in the incidence of adverse reactions (P>0.05).</p><p><strong>Conclusion: </strong>Mecobalamin combined with epalrestat substantially alleviates DPN, improves electromyogram indices, and reduces inflammatory factors and oxidative stress response, without increasing adverse reactions.</p>\",\"PeriodicalId\":7731,\"journal\":{\"name\":\"American journal of translational research\",\"volume\":\"17 4\",\"pages\":\"2898-2906\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082505/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of translational research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.62347/XUBX8834\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of translational research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/XUBX8834","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:评价甲钴胺联合依帕司他治疗糖尿病周围神经病变(DPN)的临床疗效及对炎症因子和肌电图(EMG)指标的影响。方法:回顾性分析2021年6月至2022年12月在温州医科大学衢州附属医院、衢州人民医院治疗的100例DPN患者的资料。其中,对照组45例患者单独应用甲钴胺治疗。以依帕司他加甲钴胺治疗55例为观察组。比较两组患者治疗前后炎症因子、肌电图指标、氧化应激指标、血糖水平、临床疗效、不良反应发生率的变化。结果:观察组患者总有效率显著高于对照组(P0.05)。结论:甲钙胺联合依帕司他可显著缓解DPN,改善肌电指标,降低炎症因子和氧化应激反应,且未增加不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Therapeutic effects of mecobalamin combined with epalrestat on diabetic peripheral neuropathy: reduction of inflammatory factors and improvement in electromyogram indices.

Objective: To evaluate the clinical efficacy of mecobalamin combined with epalrestat in treating diabetic peripheral neuropathy (DPN) and its effects on inflammatory factors and electromyogram (EMG) indices.

Methods: Data from 100 DPN patients treated at Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital between June 2021 and December 2022 were retrospectively analyzed. Among them, the control group was 45 patients treated with mecobalamin alone. 55 patients treated with epalrestat, in addition to mecobalamin, were the observation group. Outcomes compared between the two groups included the changes in inflammatory factors, EMG indices, oxidative stress markers, blood glucose levels before and after treatment, clinical efficacy, and the incidence of adverse reactions.

Results: The observation group showed a significantly higher overall response rate than the control group (P<0.05). After treatment, the observation group exhibited lower levels of C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), and matrix metalloproteinase-9 (MMP-9) than control group (all P<0.05). The observation group also demonstrated higher motor nerve conduction velocity (MCV) and sensory nerve conduction velocity (SCV) of the median nerve and nervus peronaeus communis compared to the control group (all P<0.05). Additionally, the observation group showed lower levels of propylene glycol and higher levels of superoxide dismutase compared to the control group (both P<0.05). Fasting blood glucose and 2-hour postprandial blood glucose levels in the observation group were significantly lower than those in the control group (P<0.05). Both groups exhibited a decrease in Michigan Diabetic Neuropathy Scores post-treatment compared to pre-treatment, with the observation group scoring lower than the control group (P<0.05). No difference was found between the 2 groups in the incidence of adverse reactions (P>0.05).

Conclusion: Mecobalamin combined with epalrestat substantially alleviates DPN, improves electromyogram indices, and reduces inflammatory factors and oxidative stress response, without increasing adverse reactions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American journal of translational research
American journal of translational research ONCOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
自引率
0.00%
发文量
552
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信